We develop the next generation potency drug.

To enhance quality of life for men and couples worldwide.

Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives.

Press Releases

Dicot Pharma’s World in Numbers

Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration from exploratory measurements in the Phase 1 study.
percent
Subscription rate in the August 2024 rights issue.

Q2 report released – Watch the interview

The Interim Report for the second quarter was released on August 12. Watch CEO Elin Trampe and CFO Björn Petersson discuss and comment on the report in an interview with Direkt Studios.

Financial calendar and events

Dutch TV highlights Swedish innovation

RTL’s channels reach 98% of the Dutch population every week. In one of their segments on innovative Swedish companies, Elin Trampe is interviewed about Dicot Pharma’s vision and the clinical work partly conducted in the Netherlands.